• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

Eli Lilly’s Mirikizumab Hits the Mark in Phase III Study, Bests Cosentyx

cafead

Administrator
Staff member
  • cafead   Jul 18, 2020 at 12:32: PM
via Eli Lilly’s experimental treatment for plaque psoriasis beat out Novartis’ vaunted drug Cosentyx in a comparison study. Mirikizumab met all primary endpoints against placebo and secondary endpoints against Cosentyx in the Phase III study, the Indianapolis-based pharma company announced.

article source
 

<